Dermatology

Biomarker analyses continue to provide insights but have not yet established clear rules for patient selection.

By Month 6 (M6), 50–60% achieved at least a one-point improvement across validated HS severity measures.

Discover a study comparing intralesional triamcinolone and methotrexate for alopecia areata, revealing superior regrowth and patient satisfaction with triamcinolone.

This study evaluated the psychometric performance and interpretability of HiSQOL using data from two multinational Phase III trials of bimekizumab in moderate-to-severe HS.

A recent study evaluated a novel 2% salicylic acid gel enriched with hydrating and soothing agents, aiming to balance acne treatment with skin barrier repair.

Apremilast shows sustained 52-week efficacy and safety in children with moderate to severe plaque psoriasis.

Discover how fewer melanoma cases with more severe features were seen during COVID, highlighting need for robust skin cancer pathways.

Biologic switching in psoriasis improves skin outcomes but requires careful infection monitoring, finds major review.